Deltex-3-like (DTX3L) stimulates metastasis of melanoma through FAK/PI3K/AKT but not MEK/ERK pathway

Oncotarget

Volumn 6, Issue 16, 2015, Pages 14290-14299

  Thang, Nguyen Dinh ^a,b   Yajima, Ichiro ^a,c   Kumasaka, Mayuko Y ^a,c   Iida, Machiko ^a,c   Suzuki, Tamio ^d   Kato, Masashi ^a,c  

^a CHUBU UNIVERSITY   (Japan)

^b VIETNAM NATIONAL UNIVERSITY   (Viet Nam)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d YAMAGATA UNIVERSITY   (Japan)

Author keywords

Cancer; Deltex 3 like; FAK PI3K AKT pathway; Melanoma; Metastasis

Indexed keywords

BIOLOGICAL MARKER; FOCAL ADHESION KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN DTX3L; PROTEIN KINASE B; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; DTX3L PROTEIN, HUMAN; FOCAL ADHESION KINASE 1; UBIQUITIN PROTEIN LIGASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MELANOCYTE; MELANOMA; METASTASIS POTENTIAL; MOLECULAR CLONING; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR INVASION; ANIMAL; C57BL MOUSE; ENZYMOLOGY; EXPERIMENTAL MELANOMA; GENETICS; METABOLISM; METASTASIS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; FOCAL ADHESION KINASE 1; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; UBIQUITIN-PROTEIN LIGASES;

EID: 84931053474     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3742     Document Type: Article

References (37)

1. Kato M, Takahashi M, Akhand AA, Liu W, Dai Y, Shimizu S, Iwamoto T, Suzuki H, Nakashima I. Transgenic mouse model for skin malignant melanoma. Oncogene. 1998; 17:1885-1888.
2. Kumasaka MY, Yajima I, Hossain K, Iida M, Tsuzuki T, Ohno T, Takahashi M, Yanagisawa M, Kato M. A novel mouse model for de novo Melanoma. Cancer research. 2010; 70:24-29.
3. Gupta PB, Kuperwasser C, Brunet JP, Ramaswamy S, Kuo WL, Gray JW, Naber SP, Weinberg RA. The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nature genetics. 2005; 37:1047-1054.
4. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006; 127:679-695.
5. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nature medicine. 2006; 12:895-904.
6. McCubrey JA, Steelman LS, Kempf CR, Chappell WH, Abrams SL, Stivala F, Malaponte G, Nicoletti F, Libra M, Basecke J, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Cocco L, Martelli AM. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. Journal of cellular physiology. 2011; 226:2762-2781.
7. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature. 2007; 445:851-857.
8. Sonoda Y, Hada N, Kaneda T, Suzuki T, Ohshio T, Takeda T, Kasahara T. A synthetic glycosphingolipidinduced antiproliferative effect in melanoma cells is associated with suppression of FAK, Akt, and Erk activation. Biological & pharmaceutical bulletin. 2008; 31:1279-1283.
9. Goundiam O, Nagel MD, Vayssade M. Growth and survival signalling in B16F10 melanoma cells in 3D culture. Cell biology international. 2010; 34:385-391.
10. Huntington JT, Shields JM, Der CJ, Wyatt CA, Benbow U, Slingluff CL, Jr, Brinckerhoff CE. Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. The Journal of biological chemistry. 2004; 279:33168-33176.
11. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Molecular plasticity of human melanoma cells. Oncogene. 2003; 22:3070-3075.
12. Hess AR, Postovit LM, Margaryan NV, Seftor EA, Schneider GB, Seftor RE, Nickoloff BJ, Hendrix MJ. Focal adhesion kinase promotes the aggressive melanoma phenotype. Cancer research. 2005; 65:9851-9860.
13. Aguiar RC, Yakushijin Y, Kharbanda S, Salgia R, Fletcher JA, Shipp MA. BAL is a novel risk-related gene in diffuse large B-cell lymphomas that enhances cellular migration. Blood. 2000; 96:4328-4334.
14. Takeyama K, Aguiar RC, Gu L, He C, Freeman GJ, Kutok JL, Aster JC, Shipp MA. The BAL-binding protein BBAP and related Deltex family members exhibit ubiquitin-protein isopeptide ligase activity. The Journal of biological chemistry. 2003; 278:21930-21937.
15. Hakme A, Huber A, Dolle P, Schreiber V. The macroPARP genes Parp-9 and Parp-14 are developmentally and differentially regulated in mouse tissues. Developmental dynamics: an official publication of the American Association of Anatomists. 2008; 237:209-215.
16. Yan Q, Dutt S, Xu R, Graves K, Juszczynski P, Manis JP, Shipp MA. BBAP monoubiquitylates histone H4 at lysine 91 and selectively modulates the DNA damage response. Molecular cell. 2009; 36:110-120.
17. Yan Q, Xu R, Zhu L, Cheng X, Wang Z, Manis J, Shipp MA. BAL1 and its partner E3 ligase, BBAP, link Poly(ADP-ribose) activation, ubiquitylation, and doublestrand DNA repair independent of ATM, MDC1, and RNF8. Molecular and cellular biology. 2013; 33:845-857.
18. Bachmann SB, Frommel SC, Camicia R, Winkler HC, Santoro R, Hassa PO. DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells. Molecular cancer. 2014; 13:125.
19. Yajima I, Kumasaka MY, Naito Y, Yoshikawa T, Takahashi H, Funasaka Y, Suzuki T, Kato M. Reduced GNG expression levels in mouse malignant melanomas and human melanoma cell lines. American journal of cancer research. 2012; 2:322-329.
20. Kato M, Iida M, Goto Y, Kondo T, Yajima I. Sunlight exposure-mediated DNA damage in young adults. Cancer epidemiology, biomarkers & prevention. 2011; 20:1622-1628.
21. Yanagishita T, Yajima I, Kumasaka M, Kawamoto Y, Tsuzuki T, Matsumoto Y, Watanabe D, Kato M. Actinbinding protein, Espin: a novel metastatic regulator for melanoma. Molecular cancer research. 2014; 12:440-446.
22. Lin K, Baritaki S, Militello L, Malaponte G, Bevelacqua Y, Bonavida B. The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-kappaB/Snail/RKIP/PTEN Circuit. Genes & cancer. 2010; 1:409-420.
23. Carlino MS, Todd JR, Rizos H. Resistance to c-Kit inhibitors in melanoma: insights for future therapies. Oncoscience. 2014; 1:423-426.
24. Eustace AJ, Kennedy S, Larkin AM, Mahgoub T, Tryfonopoulos D, O'Driscoll L, Clynes M, Crown J, O'Donovan N. Predictive biomarkers for dasatinib treatment in melanoma. Oncoscience. 2014; 1:158-166.
25. Kato M, Takeda K, Kawamoto Y, Tsuzuki T, Hossain K, Tamakoshi A, Kunisada T, Kambayashi Y, Ogino K, Suzuki H, Takahashi M, Nakashima I. c-Kit-targeting immunotherapy for hereditary melanoma in a mouse model. Cancer research. 2004; 64:801-806.
26. Ascierto PA, Simeone E, Giannarelli D, Grimaldi AM, Romano A, Mozzillo N. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. Journal of translational medicine. 2012; 10:107.
27. Goydos JS, Mann B, Kim HJ, Gabriel EM, Alsina J, Germino FJ, Shih W, Gorski DH. Detection of B-RAF and N-RAS mutations in human melanoma. Journal of the American College of Surgeons. 2005; 200:362-370.
28. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417:949-954.
29. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer research. 2003; 63:5198-5202.
30. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ, Springer CJ, Marais R. B-RAF is a therapeutic target in melanoma. Oncogene. 2004; 23:6292-6298.
31. Liang S, Sharma A, Peng HH, Robertson G, Dong C. Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation. Cancer research. 2007; 67:5814-5820.
32. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. Inhibition of mutated, activated BRAF in metastatic melanoma. The New England journal of medicine. 2010; 363:809-819.
33. Thang N, Kumasaka Y, Nghia P, Yajima I, Kato M. Treatment of vemurafenib-resistant SKMEL-28 melanoma cells with paclitaxel. Asian Pac J Cancer Prev. 2015; in press.
34. Kato M, Wickner W. Vam10p defines a Sec18pindependent step of priming that allows yeast vacuole tethering. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100:6398-6403.
35. Ohshima Y, Yajima I, Takeda K, Iida M, Kumasaka M, Matsumoto Y, Kato M. c-RET molecule in malignant melanoma from oncogenic RET-carrying transgenic mice and human cell lines. PloS one. 2010; 5:e10279.
36. Ohgami N, Ida-Eto M, Shimotake T, Sakashita N, Sone M, Nakashima T, Tabuchi K, Hoshino T, Shimada A, Tsuzuki T, Yamamoto M, Sobue G, Jijiwa M, Asai N, Hara A, Takahashi M, et al. c-Ret-mediated hearing loss in mice with Hirschsprung disease. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107:13051-13056.
37. Kato M, Kumasaka MY, Takeda K, Hossain K, Iida M, Yajima I, Goto Y, Ohgami N. L-cysteine as a regulator for arsenic-mediated cancer-promoting and anti-cancer effects. Toxicology in vitro. 2011; 25:623-629.